Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Endocrine-Related Cancer

• Publication date

  2006-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1677/ERC.1.01257PMID 17158758
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acquisition of Hormone-independent Growth in MCF-7 Cells Is Accompanied by Increased Expression of Estrogen-regulated Genes but Without Detectable DNA Amplifications

  2007cited by this paper
• Altered Target Gene Regulation Controlled by Estrogen Receptor-α Concentration

  2006cited by this paper
• Altered target gene regulation controlled by estrogen receptor-alpha concentration.

  2006cited by this paper
• Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity.

  2005cited by this paper
• Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.

  2005influential reference
• Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.

  2005cited by this paper
• Life following aromatase inhibitors – where now for endocrine sequencing?

  2005influential reference
• The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.

  2005influential reference
• Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance

  2005cited by this paper
• The future of fulvestrant ("Faslodex").

  2005cited by this paper
• Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.

  2005cited by this paper
• Loss of Estrogen Receptor Signaling Triggers Epigenetic Silencing of Downstream Targets in Breast Cancer

  2004cited by this paper
• Increases in estrogen receptor‐α concentration in breast cancer cells promote serine 118/104/106‐independent AF‐1 transactivation and growth in the absence of estrogen

  2004influential reference
• Action of “pure” antiestrogens in inhibiting estrogen receptor action

  2004cited by this paper
• Faculty Opinions recommendation of Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter.

  2004influential reference
• Estrogen receptor phosphorylation.

  2003influential reference
• Aromatase inhibitors for breast cancer: lessons from the laboratory

  2003cited by this paper
• Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation*

  2003influential reference
• Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling

  2003cited by this paper
• Estrogen Receptor-Directs Ordered , Cyclical , and Combinatorial Recruitment of Cofactors on a Natural Target

  2003influential reference
• Endocrine-responsive breast cancer and strategies for combating resistance

  2002influential reference
• Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol.

  2002influential reference
• Estrogen receptor downregulators: new antihormonal therapy for advanced breast cancer.

  2002cited by this paper
• Cellular and molecular pharmacology of antiestrogen action and resistance.

  2001influential reference
• Printed in U.S.A. Copyright © 2000 by The Endocrine Society A Role for Akt in Mediating the Estrogenic Functions of Epidermal Growth Factor and Insulin-Like Growth Factor I*

  2000cited by this paper
• The coregulator exchange in transcriptional functions of nuclear receptors.

  2000influential reference
• Proteasome-dependent degradation of the human estrogen receptor.

  1999cited by this paper
• MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.

  1997cited by this paper
• Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation.

  1996cited by this paper
• Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer.

  1993cited by this paper
• Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications.

  1993cited by this paper
• Regulation of progesterone receptor messenger ribonucleic acid and protein levels in MCF-7 cells by estradiol: analysis of estrogen's effect on progesterone receptor synthesis and degradation.

  1988cited by this paper
• Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7.

  1984cited by this paper
• Tumour cellularity, oestrogen receptors and prognosis in breast cancer.

  1983cited by this paper
• Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line.

  1982cited by this paper

• Comparative evaluation of the therapeutic strategies using a minimal model of luminal-A breast cancer.

  2023cites this paper
• Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial

  2023cites this paper
• Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model

  2022cites this paper
• Mechanistic Investigation of Site-specific DNA Methylating Agents Targeting Breast Cancer Cells.

  2021cites this paper
• Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer

  2020cites this paper
• Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells

  2020cites this paper
• Biological Evaluation of a New Brassinosteroid: Antiproliferative Effects and Targeting Estrogen Receptor α Pathways

  2019cites this paper
• The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1

  2019cites this paper
• MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1

  2019cites this paper
• Dielectrophoretic properties distinguish responses to estrogen and fulvestrant in breast cancer cells

  2018cites this paper
• Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.

  2018cites this paper
• Navigation through inter- and intratumoral heterogeneity of endocrine resistance mechanisms in breast cancer: A potential role for Liquid Biopsies?

  2017cites this paper
• Treatment for the endocrine resistant breast cancer: Current options and future perspectives.

  2017cites this paper
• Full Antagonism of the Estrogen Receptor without a Prototypical Ligand Side Chain

  2016cites this paper
• Causal Therapy of Breast Cancer Irrelevant of Age, Tumor Stage and 
ER-Status: Stimulation of Estrogen Signaling Coupled With Breast 
Conserving Surgery

  2016cites this paper
• The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistance

  2015cites this paper
• Endocrine resistance in breast cancer--An overview and update.

  2015cites this paper
• Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers

  2015cites this paper
• Induction of the CLOCK Gene by E2-ERα Signaling Promotes the Proliferation of Breast Cancer Cells

  2014cites this paper
• Estrogen receptor-α signaling and localization regulates autophagy and unfolded protein response activation in ER+ breast cancer.

  2014cites this paper
• Knockdown of estrogen receptor‐α induces autophagy and inhibits antiestrogen‐mediated unfolded protein response activation, promoting ROS‐induced breast cancer cell death

  2014cites this paper
• Modelling the effect of GRP 78 on anti-oestrogen sensitivity and resistance in breast cancer

  2013cites this paper
• Modelling the effect of GRP78 on anti-oestrogen sensitivity and resistance in breast cancer

  2013cites this paper
• Investigating epigenetic mechanisms of acquired endocrine resistance in an in vitro model of breast cancer

  2013influential citation
• The mechanism of ligand-independent activation of estrogen receptor in letrozole-resistant breast cancer cells

  2013cites this paper
• Resveratrol Sensitizes Tamoxifen in Antiestrogen-Resistant Breast Cancer Cells with Epithelial-Mesenchymal Transition Features

  2013cites this paper
• Practical synthesis of a chromene analog for use as a retinoic acid receptor alpha antagonist lead compound.

  2013cites this paper
• Glucose-regulated protein 78 controls cross-talk between apoptosis and autophagy to determine antiestrogen responsiveness.

  2012cites this paper
• δEF1 Down-Regulates ER-α Expression and Confers Tamoxifen Resistance in Breast Cancer

  2012cites this paper
• Possible aryl hydrocarbon receptor-independent pathway of 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced antiproliferative response in human breast cancer cells.

  2012cites this paper
• A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen

  2012cites this paper
• Full length TrkB potentiates estrogen receptor alpha mediated transcription suggesting convergence of susceptibility pathways in schizophrenia.

  2011cites this paper
• During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein

  2011cites this paper
• Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer

  2011cites this paper
• Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy.

  2011cites this paper
• Cancer Therapy : Preclinical Clinical Cancer Research Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G 1 Arrest in Human Breast Cancer Cells and Tumors

  2010cites this paper
• DBC-1 mediates endocrine resistant breast cancer cell survival

  2010cites this paper
• BCL2 and CASP8 regulation by NF‐κB differentially affect mitochondrial function and cell fate in antiestrogen‐sensitive and ‐resistant breast cancer cells

  2010cites this paper
• Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors

  2010cites this paper
• Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk

  2010cites this paper
• Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response.

  2010cites this paper
• Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640.

  2010cites this paper
• Genomic Effects of Hormonal Adjuvant Therapies that Could Support the Emergence of Drug Resistance in Breast Cancer

  2010cites this paper
• Systematic Mapping of Posttranslational Modifications in Human Estrogen Receptor-α with Emphasis on Novel Phosphorylation Sites*S

  2009cites this paper
• The nuclear factor kappa b (NFkb) plays a critical role in the development of antiestrogen resistance

  2009cites this paper
• XBP1, Unfolded Protein Response, and Endocrine Responsiveness

  2009cites this paper
• FKBPL regulates estrogen receptor signaling and determines response to endocrine therapy.

  2009cites this paper
• Adenosine A1 receptor, a target and regulator of ERα action, mediates the proliferative effects of estradiol in breast cancer

  2009cites this paper
• Are trefoil factors oncogenic?

  2008cites this paper
• receptor alpha, with emphasis on novel phosphorylation sites

  2008cites this paper
• Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor.

  2008cites this paper
• Rational management of endocrine resistance in breast cancer

  2008cites this paper
• The Role of the ErbB2/PI 3-K/Akt1 Pathway in the Development of Hormone Resistance in Breast Cancer

  2007cites this paper
• Progressive Loss of Estrogen Receptor α Cofactor Recruitment in Endocrine Resistance

  2007cites this paper
• The Role of the ErbB 2 / PI 3K / Akt 1 Pathway in the Development of Hormone Resistance in Breast Cancer

  2007cites this paper
• Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistance.

  2007cites this paper
• The Emerging Role of the LIV-1 Subfamily of Zinc Transporters in Breast Cancer

  2007cites this paper
• Pathways to tamoxifen resistance.

  2007cites this paper